Publications

How can we integrate the biology of breast cancer cell dormancy into clinical practice?

I. Elkholi, A. A. N. Rose, J. Aguirre-Ghiso, J. F. Cote.  (2024) Cancer Cell. https://doi.org/10.1016/j.ccell.2024.05.023

Osimertinib is associated with improved outcomes compared to first- and second-generation EGFR inhibitors in pre-treated but not untreated NSCLC leptomeningeal metastases.

D. Bian, A. Lazaratos, S. M. Maritan, A. Quaiattini, Z. Zeng, Z. Zhu, S. T. Ugur, R. Malani, Y. J. Kim, E. Ichihara, V. Cohen, A. A. N. Rose, N. Bouganim, M. Dankner. (2024)  Heliyon. Pages e29668 E-pub ahead of print.  https://doi.org/10.1016/j.heliyon.2024.e29668

A Phase 2, Single-Arm Trial Evaluating ¹³¹I-PSMA-1095 Targeted Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer.

F. Liu, C. Ferrario, P. Fallah, A. A. N. Rose, S. Labidi, A. Mamo, S. M. Probst. (2024) Nuclear Medicine Communications. Accepted – Online ahead of print. DOI:10.1097/MNM.0000000000001858

The evolving treatment landscape for BRAF-mutated non-small cell lung cancer.

M. Dankner, J. Maxwell, A. A. N. Rose. (2024)  (2024). Translational Lung Cancer Research. 2024;13(4):930-935.

https://dx.doi.org/10.21037/tlcr-24-117

Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicenter retrospective cohort study.

S. Labidi, N. Meti, R. Barua, J. Riromar, A. Hansen, D. M. Jiang, N. Fallah-Rad, S. S. Sridhar, C. Ferrario, R. Pezo, S. Cheng, A. G. Sacher, A. A. N. Rose. (2024) BMJ Open. 2024;14:e081480. https://doi.org/10.1136/bmjopen-2023-081480

Characterizing the clinical, genomic, and transcriptomic landscape of BRAF mutant cancers.

 S. Kazandjian*, E. Rousselle*, M. Dankner, D. W. Cescon, A. Spreafico, K. Ma, P. Kavan, G. Batist, A. A. N. Rose. (2024)  Cancers 16(2),445. *Equal Contribution.  https://doi.org/10.3390/cancers16020445

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.

M. Riaud, J. Maxwell, I. Soria-Bretones, M. Dankner, M. Li, A. A. N. Rose. (2024)  Nature Reviews Cancer. 24:105-122 https://doi.org/10.1038/s41568-023-00650-x

Analysis of the circulating metabolome of patients with cutaneous, mucosal and uveal melanoma reveals distinct metabolic profiles with implications for response to immunotherapy.

M. Vilbert, E. C. Koch, A. A. N. Rose, R. C. Laister, D. Gray, V. Sotov, S. Penny, A. Spreafico, D. Hogg, D. M. Pinto, M. O. Butler, S. D. Saibil. (2023)  Cancers 15(14), 3708; https://doi.org/10.3390/cancers15143708

Intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.

A. Lazaratos, S. M. Maritan, A. Quaiattini, A. Darlix, R. Ivica, E. Ferraro, G. Griguolo, A. Pellerino, S. Hofer, W. Jacot, H. Stemmler, M. P.H. van den Broek, N. Dobnikar, F. Panet, Z. Lahijanian, A. Morikawa, A. D. Seidman, R. Soffietti, L. Panasci, K. Petrecca, A. A. N. Rose, N. Bouganim, M. Dankner. (2023)  The Breast. https://doi.org/10.1016/j.breast.2023.04.008

Non-small cell lung cancer: how to manage BRAF-mutated disease.

G. Guaitoli, L. Zollo, M. Tiseo, M. Dankner, A. A. N. Rose, F. Facchinetti. (2023) Drugs in Context. 2023; 12:2022-11-3. DOI: 10.7573/dic.2022-11-3

Gender Disparities among Graduates of a Canadian MD-PhD Program.

J. M. Romero, M. Sorin, M. Danker, H. Whittaker, A. A. N. Rose, J. Trasler, M. Eisenberg. (2023) Clinical and Investigative Medicine. 46(1)2023. https://doi.org/10.25011/cim.v46i1.39965

Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer

Sathyen A Prabhu, Omar Moussa, Christophe Gonçalves, Judith H LaPierre, Hsiang Chou, Fan Huang, Vincent R Richard, Pault YM Ferruzo, Elizabeth M Guettler, Isabel Soria-Bretones, Laura Kirby, Natascha Gagnon, Jie Su, Jennifer Silvester, Sai Sakktee Krisna, April A. N. Rose, Karen E Sheppard, David W Cescon, Frédérick A Mallette, Rene P Zahedi, Christoph H Borchers, Sonia V Del Rincon, Wilson H Miller Jr. Mol Cancer Ther (2023) 22 (2): 192–204.

Clinical activity of mitogen-activated protein kinase–targeted therapies in patients with non–V600 BRAF-mutant tumors                                                                            Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A Nebhan, Ibiayi Dagogo-Jack, Nathaniel J Myall, Georg Richtig, Jillian WP Bracht, Marco Gerlinger, Eiji Shinozaki, Takayuki Yoshino, Daisuke Kotani, Jason R Fangusaro, Oliver Gautschi, Julien Mazieres, Jeffrey A Sosman, Scott Kopetz, Vivek Subbiah, Michael A Davies, Anna L Groover, Ryan J Sullivan, Keith T Flaherty, Douglas B Johnson, Andrea Benedetti, David W Cescon, Anna Spreafico, George Zogopoulos, April A. N. Rose. DOI: 10.1200/PO.22.00107 JCO Precision Oncology no. 6 (2022) e2200107. Published online August 17, 2022.

The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER+ breast cancer with mitotic aberrations                                                 Isabel Soria-Bretones, Kelsie L Thu, Jennifer Silvester, Jennifer Cruickshank, Samah El Ghamrasni, Wail Ba-Alawi, Graham C Fletcher, Reza Kiarash, Mitchell J Elliott, Jordan J Chalmers, Andrea C Elia, Albert Cheng, April AN Rose, Mark R Bray, Benjamin Haibe-Kains, Tak W Mak, David W Cescon. SCIENCE ADVANCES. 8(36). DOI: 10.1126/sciadv.abq4293

Melanomas with concurrent BRAF non-p. V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.                                   Rajkumar S, Berry D, Heney KA, Strong C, Ramsay L, Lajoie M, Alkallas R, Nguyen TT, Thomson C, Ahanfeshar-Adams M, Dankner M, Petrella T, Rose AAN, Siegel PM, Watson IR. Cell Rep. 2022 Apr 5;39(1):110634. doi: 10.1016/j.celrep.2022.110634.

HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.                                                                                                                                                                                                                                                                             Biondini M, Kiepas A, El-Houjeiri L, Annis MG, Hsu BE, Fortier AM, Morin G, Martina JA, Sirois I, Aguilar-Mahecha A, Gruosso T, McGuirk S, Rose AAN, Tokat UM, Johnson RM, Sahin O, Bareke E, St-Pierre J, Park M, Basik M, Majewski J, Puertollano R, Pause A, Huang S, Keler T, Siegel PM.Oncogene. 2022 Mar;41(12):1701-1717. doi: 10.1038/s41388-022-02206-z. Epub 2022 Feb 2.

Pegylated Liposomal Doxorubicin and Kidney-Limited Thrombotic Microangiopathy in a Kidney Transplant Recipient: A Case Report.                                                       Sonia Rodriguez-Ramirez, Kevin Yau, Abhijat Kitchlu, Rohan John, April A. N. Rose, David Hogg, S Joseph Kim. Kidney Medicine. Volume 4, Issue 5, May 2022, 10046

 Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.

Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV.
J Immunother Cancer. 2021 Jan;9(1):e001931. doi: 10.1136/jitc-2020-001931.

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN, Armstrong SM, Hogg D, Butler MO, Saibil SD, Arteaga DP, Pimentel Muniz T, Kelly D, Ghazarian D, King I, Kamil ZS, Ross K, Spreafico A.
J Immunother Cancer. 2021 Jan;9(1):e001642. doi: 10.1136/jitc-2020-001642.

Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
Kelly D, Rose AAN, Muniz TP, Hogg D, Butler MO, Saibil SD, King I, Kamil ZS, Ghazarian D, Ross K, Iafolla M, Araujo DV, Waldron J, Laperriere N, Krema H, Spreafico A.
Cancers (Basel). 2021 Jul 20;13(14):3640. doi: 10.3390/cancers13143640.

Increasing Referrals of Patients With Gastrointestinal Cancer to a Cancer Rehabilitation Program: A Quality Improvement Initiative.
Nadler MB, Rose AAN, Prince R, Eng L, Lott A, Grant RC, Jones JM, Enright K.
JCO Oncol Pract. 2021 Apr;17(4):e593-e602. doi: 10.1200/OP.20.00432. Epub 2020 Dec 8

BRAF Mutation Class and Clinical Outcomes-Letter.

Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis.